ERAP1 and cancer: However, additional studies are warranted to confirm these results and to better understand the molecular mechanisms by which secreted ERAP1 and ERAP2 could modulate neutrophil migration, as it would open new avenues for exploring their therapeutic potential in settings characterized by altered cell motility, such as autoimmune diseases and cancer metastasis.